专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2015175973A1 PROTEIN-BASED PARTICLES FOR DRUG DELIVERY 审中-公开
标题翻译：用于药物递送的基于蛋白质的颗粒
公开(公告)号：WO2015175973A1
公开(公告)日：2015-11-19
申请号：PCT/US2015/031142
申请日：2015-05-15
申请人： DANA-FARBER CANCER INSTITUTE, INC.
发明人： AMOOZGAR, Zohreh , GOLDBERG, Michael, Solomon , GRAYESKI, Phil
IPC分类号： A61K9/51
CPC分类号： A61K9/5169 , A61K9/0019 , A61K9/10 , A61K9/19 , A61K9/5192 , A61K31/337 , A61K31/4418 , A61K31/4439 , A61K31/513 , A61K31/704 , A61K45/06 , A61K2300/00
摘要： In one aspect, a method for forming particles is provided. The method may allow biocompatible particles comprising an agent (e.g., pharmaceutically active agent) to be produced absent one or more purification step (e.g., removal of excess reagent). In certain embodiments, particles, produced as described herein, can be utilized in a pharmaceutical composition and/or administered to a subject without further purification. The lack of one or more purification step may simplify manufacturing and/or minimize or eliminate the loss of agent from the particle after formation. In some embodiments, the method comprises associating albumin with an agent and crosslinking to form particles, such that little or no cytotoxic molecules are produced and/or remain after particle formation. Cross-linked albumin particles formed via the methods described herein may serve as biocompatible carriers for a variety of agents.
摘要翻译：一方面，提供了形成颗粒的方法。该方法可以允许在没有一个或多个纯化步骤（例如去除过量试剂）的情况下产生包含试剂（例如药学活性剂）的生物相容性颗粒。在某些实施方案中，如本文所述产生的颗粒可用于药物组合物和/或未经进一步纯化而施用于受试者。缺少一个或多个纯化步骤可以简化制造和/或最小化或消除形成后颗粒从试剂中的损失。在一些实施方案中，该方法包括将白蛋白与试剂结合并交联以形成颗粒，使得很少或没有细胞毒性分子在颗粒形成后产生和/或残留。通过本文所述的方法形成的交联的白蛋白颗粒可以用作各种试剂的生物相容载体。

12. 发明申请

WO2015175331A1 ASSAYS AND COMPOUNDS TO TREAT KIDNEY DISEASES 审中-公开
标题翻译：测定和化合物治疗狗瘟病
公开(公告)号：WO2015175331A1
公开(公告)日：2015-11-19
申请号：PCT/US2015/029832
申请日：2015-05-08
申请人： RUSH UNIVERSITY MEDICAL CENTER
发明人： GUPTA, Vineet , REISER, Jochen
IPC分类号： C12N5/071 , C12Q1/68 , C07D239/12
CPC分类号： G01N33/502 , A61K31/352 , A61K31/4409 , A61K31/4418 , A61K31/472 , A61K31/4745 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/52 , A61K31/55 , C12N5/0686 , C12N2503/02 , G01N33/5023 , G01N33/5026 , G01N33/5032 , G01N2500/10 , G02B21/0028
摘要： Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects in a patient's podocytes and methods of identifying kidney disease causing agents in a patient's biological sample are also provided.
摘要翻译：提供了治疗肾脏疾病和保护足细胞免受损伤的方法。还提供了用于治疗肾脏疾病的筛选剂的方法。此外，还提供了确定患者足细胞中的结构或功能缺陷的方法以及鉴定患者生物样品中肾脏疾病引发剂的方法。

13. 发明申请

WO2015169944A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS 审中-公开
标题翻译：用于治疗眼睛疾病和疾病的化合物
公开(公告)号：WO2015169944A1
公开(公告)日：2015-11-12
申请号：PCT/EP2015/060166
申请日：2015-05-08
申请人： PANOPTES PHARMA GES.M.B.H.
发明人： SPERL, Stefan , OBERMAYR, Franz
IPC分类号： A61K31/196 , A61K31/341 , A61K31/381 , A61K31/42 , A61K31/44 , A61K31/4704 , A61P27/02 , A61K31/4402
CPC分类号： A61K31/381 , A61K9/0048 , A61K31/196 , A61K31/277 , A61K31/341 , A61K31/42 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K47/10 , A61K47/32 , A61K47/38
摘要： The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
摘要翻译：本发明一般涉及眼部治疗领域及其用于人或动物的发展。更具体地，涉及DHODH抑制剂化合物及其用于治疗眼科疾病和病症的用途。本发明还涉及这种眼用组合物的局部给药，特别涉及其玻璃体内给药。本发明还涉及治疗活性剂的控制释放制剂，特别是眼内施用的DHODH抑制剂化合物，特别是在眼后段。

14. 发明申请

WO2015153252A1 ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER 审中-公开
标题翻译：用于治疗癌症的抗血管和抗血管肽化合物类似物
公开(公告)号：WO2015153252A1
公开(公告)日：2015-10-08
申请号：PCT/US2015/022624
申请日：2015-03-26
申请人： XAVIER UNIVERSITY OF LOUISIANA
发明人： WANG, Guangdi , ZHENG, Shilong , ZHONG, Qiu , ZHANG, Qiang
IPC分类号： C07D213/30 , C07D213/61 , A61K31/4418 , A61P35/00
CPC分类号： C07D213/61 , A61K31/4418 , A61K31/4425 , A61K45/06 , C07D213/30
摘要： Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.
摘要翻译：本发明提供了组合复方及其药学上可接受的盐，以及包含考布他汀类似物化合物的药物组合物，以及考丁胺汀类似物化合物的单独使用或与至少一种其它治疗剂组合用于治疗癌症，特定的癌症呈现为转移性肿瘤。

15. 发明申请

WO2015120350A2 COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE 审中-公开
标题翻译：用于治疗纤维性疾病的组合物和方法
公开(公告)号：WO2015120350A2
公开(公告)日：2015-08-13
申请号：PCT/US2015/014939
申请日：2015-02-07
申请人： EFFECTOR THERAPEUTICS, INC.
发明人： APPLEMAN, James , THOMPSON, Peggy, A.
IPC分类号： C12Q1/68
CPC分类号： A61K31/713 , A61K31/155 , A61K31/16 , A61K31/357 , A61K31/4245 , A61K31/436 , A61K31/4418 , A61K31/496 , A61K31/519 , A61K31/706 , A61K45/06
摘要： The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.
摘要翻译：本公开涉及用于治疗或预防纤维化病症或疾病的组合物和方法。

16. 发明申请

WO2015096654A1 SHH信号通路特异性抑制剂的应用审中-公开
公开(公告)号：WO2015096654A1
公开(公告)日：2015-07-02
申请号：PCT/CN2014/094178
申请日：2014-12-18
申请人：中国科学院上海生命科学研究院
发明人：王以政 , 冯昇杰 , 马韶蓉 , 贾彩霞
IPC分类号： A61K31/58 , A61K31/4418 , A61P25/08
CPC分类号： A61K31/4418 , A61K31/4402 , A61K31/58
摘要：本发明涉及SHH信号通路特异性抑制剂的应用。首次揭示了SHH信号通路和神经网络兴奋性有着密切的关系，参与了癫痫的形成与发展，从而可以作为药物靶点，用于开发改善或治疗癫痫的药物。还揭示了可起到延缓癫痫发生的SHH信号通路的特异性抑制剂，可以作为改善或治疗癫痫的药物。

17. 发明申请

WO2014133541A3 METHOD AND SYSTEM FOR TREATMENT OF CARDIOVASCULAR DISORDERS 审中-公开
标题翻译：用于治疗心血管疾病的方法和系统
公开(公告)号：WO2014133541A3
公开(公告)日：2015-06-18
申请号：PCT/US2013028579
申请日：2013-03-01
申请人： CORMATRIX CARDIOVASCULAR INC
发明人： MATHENY ROBERT G
IPC分类号： A61M1/10 , A61K35/34
CPC分类号： A61K35/12 , A61K31/138 , A61K31/166 , A61K31/167 , A61K31/22 , A61K31/277 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/4166 , A61K31/4418 , A61K31/505 , A61K31/5377 , A61K35/22 , A61K35/30 , A61K35/34 , A61K35/36 , A61K35/38 , A61K35/39 , A61K35/42 , A61K35/50 , A61K38/18 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1858 , A61K38/1866 , A61K38/191 , A61K2300/00
摘要： Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.
摘要翻译：用于治疗心血管疾病的方法包括将一种或多种基于细胞外基质（ECM）的组合物直接施用于与心血管疾病相关的受损或患病的心血管组织并提供心室辅助。在优选的实施方案中，基于ECM的组合物包括衍生自哺乳动物来源的ECM材料。

18. 发明申请

WO2013169979A3 POLYMORPH COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF 审中-公开
标题翻译：多晶型组合物，制备方法及其用途
公开(公告)号：WO2013169979A3
公开(公告)日：2015-06-18
申请号：PCT/US2013040265
申请日：2013-05-09
申请人： EDGE THERAPEUTICS INC , EVONIK CORP
发明人： MACDONALD R LOCH , DAVIS CARA R , BURTON KEVIN , WINCHESTER GARY , STELLA ANGELA R
IPC分类号： A61K9/50
CPC分类号： A61K9/146 , A61K9/1647 , A61K9/1682 , A61K9/1694 , A61K31/4418 , A61K31/4422
摘要： The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
摘要翻译：所描述的发明提供了生物活性剂如尼莫地平的基本上纯的晶体形式的可流动缓释微粒组合物的可生物降解的生物相容性递送系统，制备治疗形式的基本上纯的晶体形式的生物活性治疗由哺乳动物的脑损伤引起的中断危险的蛛网膜下腔中脑动脉中断的方法，该方法减少至少一种与脑损伤有关的迟发性并发症的体征或症状。

19. 发明申请

WO2015021134A2 TARGET BINDING MOLECULES IDENTIFIED BY KINETIC TARGET-GUIDED SYNTHESIS 审中-公开
标题翻译：由目标引导综合确定的目标结合分子
公开(公告)号：WO2015021134A2
公开(公告)日：2015-02-12
申请号：PCT/US2014/049916
申请日：2014-08-06
申请人： UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) , THE PENN STATE RESEARCH FOUNDATION
发明人： MANETSCH, Roman , NACHEVA, Katya, Pavlova , FLANIGAN, David, Lawrence , NAMELIKONDA, Niranjan, Kumar , IYAMU, Iredia, David , KULKARNI, Sameer, Shamrao , BARBER, Megan, M. , TIPTON, Jeremiah, Dwayne , WANG, Hong-Gang , DOI, Kenichiro
IPC分类号： A61K31/665 , C12Q1/68
CPC分类号： G01N33/6848 , A61K31/18 , A61K31/343 , A61K31/36 , A61K31/4015 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/4155 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4418 , A61K31/443 , A61K31/451 , A61K31/454 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/5415 , G01N33/6845 , G01N2560/00 , H01J49/0036 , H01J49/004
摘要： Methods of identifying target binding molecules by target guided synthesis are provided. The methods include providing two or more fragments capable of reacting to form the target binding molecule and mixing the fragments with the target. The methods can be used to identify target binding molecules that bind targets such as proteins or nucleic acids, including those that bind shallow binding pockets on the surface of such targets. The methods are applied to the Bcl-XL and Mcl-1 proteins from the Bcl-2 family of proteins. Using thio acid and sulfonyl azide fragments capable of reacting through sulfo-click chemistry, new acyl sulfonamides are identified that bind one o both of the Bcl-XL and Mcl-1 proteins. Pharmaceutical formulations of these target binding molecules are also provided.
摘要翻译：提供了通过靶引导合成鉴定靶结合分子的方法。所述方法包括提供两种或更多种能够反应以形成靶结合分子的片段并将片段与靶混合。该方法可以用于鉴定结合靶标的靶标结合分子，例如蛋白质或核酸，包括与这些靶标表面上的浅结合口袋相结合的靶分子。该方法应用于来自Bcl-2家族蛋白质的Bcl-XL和Mcl-1蛋白质。使用能够通过磺基点击化学反应的硫酸和磺酰叠氮化物片段，鉴定出新的酰基磺酰胺，其结合Bcl-XL和Mcl-1两者中的一种。还提供了这些靶结合分子的药物制剂。

20. 发明申请

WO2014199905A1 MEDICAMENT FOR TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：治疗阿尔茨海默病的药物
公开(公告)号：WO2014199905A1
公开(公告)日：2014-12-18
申请号：PCT/JP2014/065025
申请日：2014-05-30
申请人： RESEARCH FOUNDATION ITSUU LABORATORY
发明人： KAWAHARA, Kohichi , SUENOBU, Michita , SHUDO, Koichi
IPC分类号： A61K45/00 , A61K31/196 , A61K31/554 , A61P25/28 , A61P43/00
CPC分类号： A61K31/554 , A61K31/192 , A61K31/203 , A61K31/4418 , A61K31/55 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： A medicament for therapeutic and/or preventive treatment of Alzheimer's disease, which comprises a combination of a retinoic acid receptor (RAR) agonist such as Am80 and a retinoid X receptor (RXR) agonist such as HX630.
摘要翻译：一种用于治疗和/或预防性治疗阿尔茨海默病的药物，其包括视黄酸受体（RAR）激动剂如Am80和类视黄醇X受体（RXR）激动剂如HX630的组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式